Biocure Technology, Inc. engages in the development and commercialization of biosimilar products. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2008-03-27. The firm specializes in the development and commercialization of its own CAR T-cell therapy, targeting Chronic lymphocytic leukemia and solid tumor cancers. Additionally, the Company is developing biosimilar technologies for cancer treatment. The Company’s products include Interferon Beta, Ranibizumab and PEG-Filgrastim.
Le segment de revenus le plus important est Biocure Technology Inc, avec un chiffre d'affaires de Surface lors du dernier rapport de résultats. En termes géographiques, United States est le marché principal pour Biocure Technology Inc, avec un chiffre d'affaires de 1,521,124.